Abstract library

1941 results for "neuroendocrine tumors of the pancreas".
#106 Gastroenteropancreatic neuroendocrine tumors: single institution clinicopathological study
Introduction: Neuroendocrine cells are widely distributed throughout the body, and neoplasms from these dispersed cells can arise at many sites. They are distinguished into two broad categories: 1) Tumors identified as small cell lung carcinomas with biology and natural history of a high-grade malignancy and characteristics of small cell undifferentiated or anaplastic appearance by light microscopy. The WHO categorizes these tumors as poorly-differentiated neuroendocrine carcinomas; 2) Well-defined neuroendocrine tumors (NETs) with variable, but most lyindolent biologic behavior and characteristic well-differentiated histologic features. The majority arise in the gastrointestinal tract and collectively they are referred as gastroenteropancreatic neuroendocrine tumors (GEP/NETs). They include carcinoid tumors, pancreatic islet cell tumors (gastrinoma, insulinoma, glucagonoma, VIPoma, somatostatinoma), paragangliomas, pheochromocytomas, and medullary thyroid carcinomas. The WHO classifies the GEP/NETs as well-differentiated NETs (carcinoid tumors) if they are noninvasive and have benign behavior or uncertain malignant potential. In contrast, GEP/NETs with characteristics of low-grade malignancy with invasion of the muscularis propria or beyond, or metastases, are characterized as well-differentiated neuroendocrine carcinomas (malignant carcinoids). Pancreatic islet cell tumors, whether functioning or not, are classified as well-differentiated NETs or well-differentiated neuroendocrine carcinomas, due to the (depending on) histologic characteristics. The WHO classification for gastroenteropancreatic NETs based on stage (ie size and presence of metastases) and grade (mitotic rate, perineural and lymphovascular invasion, Ki-67 proliferative index) categorizes them as well-differentiated NETs, e.g., carcinoid tumors, or as well-differentiated neuroendocrine carcinomas.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Michael M. Vaslamatzis
Authors:
#110 Slug represents an important regulator of E-cadherin expression in neuroendocrine tumor cells of the pancreas
Introduction: Neuroendocrine tumors of the pancreas form an inhomogenous group of epithelial neoplasms. They differ from other types of pancreatic cancers by showing an extended survival of patients, which is due to a mostly slow proliferation rate of the tumor. However, some of these neuroendocrine tumors are characterized by an early onset of metastases, which cannot be predicted by any available method. The epithelial to mesenchymal transition (EMT) represents a central part of cell migration and metastasis. During EMT, cells loosen their cellular contacts, leave the tissue, and become migrating single cells. One of the integral compounds of cell adhesion represents the E-cadherin adhesion module, which contains mostly E-cadherin and several catenins. A loss of this adhesion module is associated with tumor progression, migration and metastasis in many types of cancer.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Alexander K├Ânig
Authors:
#141 Incidence of second primary tumors in patients with neuroendocrine tumors
Introduction: Based on epidemiological data from SEER 1950-1999, 22.4% cases of non-carcinoid second primary tumors have been described in patients diagnosed with neuroendocrine tumors. The incidence of this type of tumors varies, depending on the series assessed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Juan Manuel OConnor
Authors:
#286 Aberrant Expression of FSH Receptor in Pancreatic Neuroendocrine Tumors
Introduction: FSH receptor (FSHR) expression is restricted to gonads. FSHR plays an important role in regulation of ovarian angiogenesis. Recently, FHSR expression has been shown in blood vessels of various tumors.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof Fausto Bogazzi
Authors:
#520 Left Pancreatectomy for Neuroendocrine Pancreatic Tumors
Introduction: Distal pancreatectomy for neuroendocrine tumors localized in the body-tail of the pancreas (NTP) can be performed either with splenectomy (DP) or with a spleen-preserving procedure (SPLP).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Claudio Pasquali
Authors:
#522 Effects of Transarterial Chemoembolization of Liver Metastases from Neuroendocrine Tumors on Clinical Outcome
Introduction: Trans-catheter arterial chemoembolization (TACE) is a method of treatment of non-resectable liver metastases from neuroendocrine tumors (NET) which provides control of clinical symptoms and tumor growth.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Sanja Ognjanovic
Authors:
#531 Long-Term Outcomes in 50 Consecutive Patients with Neuroendocrine Tumors of the Pancreas
Introduction: Recently, the new World Health Organization (WHO) classification and TNM staging for neuroendocrine tumors of the pancreas (pNETs) were published.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Takeshi Natori
Authors:
#777 Laparoscopic Surgery of Functioning Neuroendocrine Tumors of Pancreas
Introduction: Laparoscopic surgery is a feasible technique for benign pancreatic pathologies and has been increasingly reported for neuroendocrine tumors of the pancreas.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Viktor Shkarban
Authors:
#827 Neuroendocrine Tumors of the Pancreas Grade 2 with Ki-67 Index More Than 5% and with Expression Cytokeratin 19 are the Risk Group of Rapid Progression
Introduction: Cytokeratin 19 (CK19) is the marker of pluripotent cells of the epithelium of the pancreatic ducts, which is not detected in differentiated endocrine cells. Our experience shows that many patients with neuroendocrine tumors of the pancreas (pNET) G2 have a rapid progression of the disease a few years after diagnosis, and metastases are found most commonly in the liver.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: MD Larisa Gurevich
Authors:
#867 Mixed Adenoneuroendocrine Carcinoma (MANECs): A Rare and Challenging Subgroup of Neuroendocrine Neoplasia
Introduction: Mixed Adenoneuroendocrine Carcinomas (MANECs) are rare entities in which at least 30% of neoplastic cells are neuroendocrine in nature (WHO 2010 classification). They result either from two independent lesions that merge together or are unique lesions with different cell populations intermingled.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Dr Conor Mosli Lynch
Authors: